Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

IRMDBullishEarningsShort Term

High materiality8/10

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

StockNews.AIJul 31, 8:15 AM EDT1 source

Trading thesisImportance 8/10

Bullish into 2H2026 as the 3870 ramp drives margin expansion and orders.

AI summary

What happened and why it matters

Iradimed reported Q2 2026 revenue of $20.5 million with GAAP EPS of $0.41 and non-GAAP EPS of $0.46. The company highlighted the 3870 MRI-compatible IV pump ramp and record domestic monitor bookings, signaling accelerating mix shifts and potential margin gains in H2. Guidance for 2026 remains intact at $91–96 million in revenue with $1.90–2.05 GAAP EPS and $2.09–2.24 non-GAAP EPS.

3870 pump ramp and quad-stack orders imply accelerating revenue mix.
Record domestic monitor bookings indicate broader adoption of MRI-compatible tech.
Guidance reaffirmation supports earnings visibility and multiple expansion potential.
20-cent quarterly dividend provides income; may support share support.

Sentiment rationale

Positive earnings trajectory, strategic product ramp (3870) with high-margin potential, and reaffirmed guidance reduce downside risk; dividend adds modest yield, supporting near-term upside.

Key facts

01
Q2 2026 revenue $20.5M, up 0.5% YoY; GAAP EPS $0.41, non-GAAP $0.46.
02
3870 MRI-compatible IV pump ramp underway; initial shipments met plan; margin uplift expected H2.
03
Domestic monitor bookings hit a record; over 70% of pump orders are quad-stack.
04
Full-year 2026 guidance reaffirmed: revenue $91-96M; GAAP EPS $1.90-2.05; non-GAAP $2.09-2.24.
05
Quarterly dividend declared at $0.20 per share; payable Aug 28, 2026.

Earnings

Category: Earnings. IRMD delivered quarterly results, reiterated 2026 guidance, and highlighted a key product ramp and bookings momentum, suggesting potential margin expansion and earnings visibility into 2H2026.